Biocon shares gain after unit gets Health Canada nod for drug that treats autoimmune conditions

October 23, 2025
Uncategorized

Biocon Biologics, a fully-integrated global biosimilars company, said it received approval for the Yesintek and Yesintek IV (ustekinumab injection), a biosimilar to Stelara IV on October 17.

Biocon shares gain after unit gets Health Canada nod for drug that treats autoimmune conditions

Leave a ReplyCancel Reply

Waaree Energies wins 300 MW wind power project in Gujarat with 25-year supply deal

AMD and Meta expand strategic partnership to deploy 6 gigawatts of AMD GPUs for AI infrastructure

EXCLUSIVE | Noel Tata set 3 conditions for backing N Chandrasekaran’s 5-year reappointment at Tata Sons

Lupin gets US FDA nod for Brivaracetam oral solution, launches in US market

SEC closes probe into alleged improper payments by Dr. Reddy’s, no enforcement action recommended